Search research articles
Contact Us
Filters
Showing results (71-80 of 86) with videos related to
Page
of 9
Sort By:
Journal of the National Cancer Institute
|
April 19, 2013
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis
Chee Khoon Lee, Chris Brown, Richard J Gralla, et al.
The New England Journal of Medicine
|
October 17, 2025
Survival with Osimertinib plus Chemotherapy in <i>EGFR</i>-Mutated Advanced NSCLC
Pasi A Jänne, David Planchard, Kunihiko Kobayashi, et al.
Cancer Discovery
|
June 30, 2022
Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Peter Savas, Louisa L Lo, Stephen J Luen, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 20, 2025
Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations
Adel Shahnam, Alexander Davis, Lauren Julia Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 2, 2023
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer
Pasi A Jänne, David Planchard, Kunihiko Kobayashi, et al.
Cancer Discovery
|
April 11, 2022
Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Mengzhao Wang, James Chih-Hsin Yang, Paul L Mitchell, et al.
Clinical Lung Cancer
|
September 23, 2022
Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations
Myung-Ju Ahn, Marvin Jonne L Mendoza, Nick Pavlakis, et al.
BMJ Open
|
July 5, 2024
Protocol for a systematic review with prospective individual patient data meta-analysis in EGFR-mutant NSCLC with brain metastases to assess the effect of SRS+osimertinib compared to osimertinib alone: the STARLET Collaboration
Kristy P Robledo, Shilo Lefresne, Yu Yang Soon, et al.
JTO Clinical and Research Reports
|
January 29, 2025
Durvalumab, Tremelimumab, and Platinum Chemotherapy in <i>EGFR</i> Mutation-Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)
Chee Khoon Lee, Bin-Chi Liao, Shalini Subramaniam, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 28, 2026
Consensus statement on ctDNA minimal residual disease (MRD) testing in early-stage NSCLC - A Delphi study by the Asian Thoracic Oncology Research Group (ATORG)
Aaron C Tan, Bin-Chi Liao, Molly Li, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 86) with videos related to
Sort By:
Page
of 9
Journal of the National Cancer Institute
|
April 19, 2013
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis
Chee Khoon Lee, Chris Brown, Richard J Gralla, et al.
The New England Journal of Medicine
|
October 17, 2025
Survival with Osimertinib plus Chemotherapy in <i>EGFR</i>-Mutated Advanced NSCLC
Pasi A Jänne, David Planchard, Kunihiko Kobayashi, et al.
Cancer Discovery
|
June 30, 2022
Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Peter Savas, Louisa L Lo, Stephen J Luen, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 20, 2025
Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations
Adel Shahnam, Alexander Davis, Lauren Julia Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 2, 2023
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer
Pasi A Jänne, David Planchard, Kunihiko Kobayashi, et al.
Cancer Discovery
|
April 11, 2022
Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Mengzhao Wang, James Chih-Hsin Yang, Paul L Mitchell, et al.
Clinical Lung Cancer
|
September 23, 2022
Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations
Myung-Ju Ahn, Marvin Jonne L Mendoza, Nick Pavlakis, et al.
BMJ Open
|
July 5, 2024
Protocol for a systematic review with prospective individual patient data meta-analysis in EGFR-mutant NSCLC with brain metastases to assess the effect of SRS+osimertinib compared to osimertinib alone: the STARLET Collaboration
Kristy P Robledo, Shilo Lefresne, Yu Yang Soon, et al.
JTO Clinical and Research Reports
|
January 29, 2025
Durvalumab, Tremelimumab, and Platinum Chemotherapy in <i>EGFR</i> Mutation-Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)
Chee Khoon Lee, Bin-Chi Liao, Shalini Subramaniam, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 28, 2026
Consensus statement on ctDNA minimal residual disease (MRD) testing in early-stage NSCLC - A Delphi study by the Asian Thoracic Oncology Research Group (ATORG)
Aaron C Tan, Bin-Chi Liao, Molly Li, et al.
Page
of 9